Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Director departure
Appointed director

Predictive Oncology Inc. (AIPT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/10/2023 8-K Quarterly results
Docs: "Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business Update Company to host investor call and webcast today, August 10th, at 5:30pm EDT PITTSBURGH, Aug. 10, 2023 -- Predictive Oncology , a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three and six months ended June 30, 2023, and provided a corporate update. The company reported a net loss of $3.9 million on total net revenue of $0.5 million for the second quarter 2023. Q2 2023 and Recent Highlights: Initiated PEDAL-Cancer Research Horizons collabor..."
05/15/2023 8-K Quarterly results
Docs: "Predictive Oncology Reports First Quarter 2023 Financial Results and Provides Business Update Company to host investor call and webcast today, May 15th, at 5:30pm EDT EAGAN, Minn., May 15, 2023 -- Predictive Oncology , a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three months ended March 31, 2023, and provided a corporate update. The company reported a net loss of $3.4 million on total net revenue of $0.2 million for the first quarter 2023. Q1 2023 and Recent Highlights: Announced groundbreaking partnership with Cancer Research Ho..."
05/08/2023 8-K Regulation FD Disclosure  Interactive Data
05/02/2023 8-K Quarterly results
04/20/2023 8-K Quarterly results
04/05/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
03/21/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update EAGAN, Minn., March 21, 2023 -- Predictive Oncology Inc. , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments laboratory and Good Manufacturing Practices facility, to accelerate oncology drug discovery and enable drug development, today reported financial and operating results for the year ended December 31, 2022, and provided a corporate update. The company reported a net loss of $25.7 million on total net revenue of $1.5 million for the full year. 2022 Highlights: Successfully completed Discovery 21, establishing proof-of-concept for the PEDAL™ drug discover..."
03/16/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Predictive Oncology Announces Distribution of Series F Preferred Stock to Holders of its Common Stock"
03/14/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Predictive Oncology Engages LifeSci Advisors as Strategic Investor Relations Partner Comprehensive, multi-faceted IR program to focus on raising awareness of Predictive Oncology and its portfolio of unique, proprietary assets capable of accelerating oncologic drug discovery and enabling drug development"
03/13/2023 8-K Other Events  Interactive Data
02/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer EAGAN, Minn., Feb. 03, 2023 -- Predictive Oncology Inc. is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead all business development, partnering and growth strategies for Predictive Oncology. As a key member of the executive team, Dr. Bush will spearhead the company’s strategic, operational and financial planning initiatives for both existing customers and emerging new markets. She will work closely with the company’s senior management in leveraging and expanding its portfolio of proprietary solutions to advance drug discovery and enable oncology drug development for the company’s biopharma partners. “In terms of scientific intelligence, industry insi..."
12/05/2022 8-K Quarterly results
12/02/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/25/2022 8-K Quarterly results
10/20/2022 8-K Quarterly results
09/16/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Transition and Separation Agreement by and between J. Melville Engle and Predictive Oncology Inc",
"Predictive Oncology Announces CEO Retirement"
09/14/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amendment to Second Amended and Restated Bylaws of Predictive Oncology Inc."
08/11/2022 8-K Quarterly results
07/26/2022 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "Amended and Restated Employment Agreement, effective as of August 1, 2022, by and between Julia Kirshner and Predictive Oncology Inc",
"Predictive Oncology Strengthens Business with Appointment of a Chief Scientific Officer and Consolidation and Expansion of its Research and Development Arm"
05/23/2022 8-K Quarterly results
05/18/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/31/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
02/18/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
01/04/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
12/27/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Predictive Oncology Adjourns Annual Meeting of Stockholders to December 30, 2021"
12/01/2021 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhi...
Docs: "EXHIBITS",
"Predictive Oncology Acquires zPREDICTA, Inc. zPREDICTA has developed a patented tumor-specific 3D cell culture platform that is complementary to Predictive Oncology’s Artificial Intelligence platform developed by Helomics. zPREDICTA’s uniquely designed 3D culture systems create a tumor microenvironment that is closer to the patient’s actual tumor than the currently available alternatives. EAGAN, Minn., Dec. 01, 2021 -- Predictive Oncology, , a knowledge-driven company focused on applying artificial intelligence to develop personalized cancer therapies, today announced the acquisition of zPREDICTA, a company pioneering tumor-specific in vitro 3D cell culture models for drug discovery and development. The acquisition immediately adds a new anticipated revenue stream to Predictive Oncology an..."
11/10/2021 8-K Quarterly results
Docs: "Predictive Oncology Reports Third Quarter Financial Results EAGAN, Minn., Nov. 10, 2021 -- Results from the third quarter show strong potential for future growth, said Predictive Oncology today, announcing financial results for the quarter ended September 30, 2021. All three of Predictive Oncology’s reportable segments recognized revenue for the quarter, and the loss per common share was reduced to $0.08, compared to $0.46 for the same period in 2020. The knowledge-driven company, which is applying artificial intelligence to personalized medicine and drug discovery, also provided an update on its business activities. Highlights from the quarter include: “We are looking forward to the outcome of our Discovery 21 program, which we believe will realize our goal of providing pharmaceutical com..."
09/15/2021 8-K Quarterly results
08/19/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy